Licensing, Acquisitions and other Arrangements (Tables)

12 Months Ended

Dec. 31, 2015

Licensing, Acquisitions and Other Arrangements

Schedule of consideration paid

(in millions)
Fair value of AbbVie common stock issued to Pharmacyclics stockholders	$	8,405
Cash consideration paid to Pharmacyclics stockholders		11,749
Cash consideration paid to Pharmacyclics equity award holders		616
Total consideration	$	20,770

Schedule of fair value of the assets acquired and liabilities assumed

        The following table summarizes preliminary fair values of assets acquired and liabilities assumed as of the May 26, 2015 acquisition date:

(in millions)
Assets acquired and liabilities assumed
Cash and equivalents	$	877
Short-term investments		11
Accounts and other receivables		106
Inventories		492
Other assets		212
Intangible assets
Definite-lived developed product rights		4,590
Definite-lived license agreements		6,780
Indefinite-lived research and development		7,180
Accounts payable and accrued liabilities		(381	)
Deferred income taxes		(6,453	)
Other long-term liabilities		(254	)
Total identifiable net assets		13,160
Goodwill		7,610
Total assets acquired and liabilities assumed	$	20,770

Schedule of pro forma combined results of operations

years ended December 31 (in millions, except per share data)	2015		2014
Net revenues	$	23,215	$	20,690
Net earnings	$	5,345	$	812
Basic earnings per share	$	3.18	$	0.47
Diluted earnings per share	$	3.16	$	0.47